Live Breaking News & Updates on Child Pugh Class|Page 5
Stay updated with breaking news from Child pugh class. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Salix Pharmacetuicals Will Present Scientific Data Featuring Post Hoc Analyses For RELISTOR® (Methylnaltrexone Bromide) At ASRA s 46th Annual Spring Meeting News provided by Share this article Share this article BRIDGEWATER, N.J., May 13, 2021 /PRNewswire/ Salix Pharmaceuticals ( Salix ), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, today announced that two RELISTOR® (methylnaltrexone bromide) scientific posters will be presented at the 46th Annual Regional Anesthesiology and Acute Pain Medicine Meeting being held May 13 – 15, 2021. The meeting is hosted by The American Society of Regional Anesthesia and Pain Medicine (ASRA). The following posters will be presented on Thursday, May 13 from 10:30 a.m. – 12:00 p.m. ET: ....
New England Journal of Medicine. Terlipressin is an investigational product and its safety and effectiveness have not yet been established by the U.S. Food and Drug Administration (FDA) or Health Canada. As previously announced, the Phase 3 CONFIRM study met its primary endpoint of Verified HRS Reversal, which is defined as renal function improvement, avoidance of dialysis and short-term survival. The main objective of the CONFIRM study was to assess the efficacy and safety of terlipressin, together with albumin, versus placebo in adults in the U.S. and Canada with cirrhosis and HRS-1. The trial met three of the four pre-specified secondary endpoints of the study including HRS reversal, ....